CyberGene
CyberGene AB is a Swedish molecular diagnostics company (founded 1995, Solna) that developed and sold proprietary diagnostic products for aneuploidy testing and male infertility testing, serving healthcare providers and diagnostic laboratories. Acquired by Devyser Diagnostics AB in April 2026 for ~SEK 12.2 million.
- Company typePrivate
- Founded1995
- HeadquartersSolna, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What CyberGene does
CyberGene AB is a Swedish molecular diagnostics company founded in 1995 and headquartered in Solna, Sweden. The company developed and marketed diagnostic products in two specialized clinical areas: aneuploidy testing (chromosomal abnormality detection used in prenatal and reproductive health contexts) and male infertility testing. Its products were positioned to medical diagnostic laboratories and healthcare providers requiring molecular diagnostics solutions in reproductive genetics. The company operated with a small team of 1-10 employees and was a wholly-owned subsidiary of the Level Bio AB Group for an extended period prior to its divestiture.
The company's business model centered on the development, manufacture, and sale of proprietary diagnostic kits/tests in niche reproductive health segments. Pricing was not publicly disclosed, and no direct revenue figure was reported; however, the 2026 transaction terms imply 2025 net revenue of approximately SEK 7.2 million (~USD 0.83 million), calculated from the disclosed 1.7x revenue acquisition multiple. CyberGene served a vertical customer base of healthcare providers and diagnostic laboratories, with a focused, use-case-driven segmentation approach.
In February 2026, Devyser Diagnostics AB announced an agreement to acquire 100% of CyberGene shares from Level Bio AB for approximately SEK 12.2 million (~USD 1.4 million) via a directed new share issue. The transaction received regulatory clearance from the Swedish Inspectorate of Strategic Products under the Foreign Direct Investments Act and closed on April 1, 2026. Post-acquisition, CyberGene's products are being integrated into Devyser's diagnostic portfolio, with the deal expected to strengthen Devyser's aneuploidy and male infertility offering and have a positive impact on gross profit and EBIT. CyberGene's prior funding history includes an early-stage investment from Sting, a Swedish startup accelerator/investor network.
CyberGene firmographics
Firmographics- Name
- CyberGene
- Legal name
- CyberGene AB
- Website
- https://cybergene.com
- Company type
- Private
- Founded year
- 1995
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- CyberGene AB is a Swedish molecular diagnostics company (founded 1995, Solna) that developed and sold proprietary diagnostic products for aneuploidy testing and male infertility testing, serving healthcare providers and diagnostic laboratories. Acquired by Devyser Diagnostics AB in April 2026 for ~SEK 12.2 million.
- Ownership category
- akta.pro rank
CyberGene industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)
- akta.pro secondary industries
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where CyberGene is headquartered
LocationHeadquarters
- HQ city
- Solna
- HQ country
- Sweden
- HQ region
- Europe
Markets served
CyberGene business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations
CyberGene product offering
Product offeringCore offering
CyberGene is a Swedish molecular diagnostics company that develops and markets diagnostic testing products in two areas: aneuploidy testing (detecting chromosomal abnormalities in prenatal and reproductive health contexts) and male infertility testing. The products are sold to medical diagnostic laboratories and healthcare providers, supporting reproductive-health and genetic-screening workflows.
Product overview
CyberGene is a Swedish molecular diagnostics company that develops and markets products in the fields of aneuploidy and male infertility testing. The company operated as a subsidiary within the Level Bio AB group until its acquisition by Devyser Diagnostics AB in April 2026. CyberGene's portfolio consists of two core product categories: aneuploidy testing products and male infertility testing products, both serving the molecular diagnostics market.
Differentiator
Problem solved
Functional benefit
Products and services
- Aneuploidy Testing Products Diagnostic products used to detect chromosomal abnormalities (aneuploidy) in prenatal and reproductive health contexts, sold to medical diagnostic laboratories and healthcare providers.
- Male Infertility Testing Products Diagnostic products for male infertility testing, supporting reproductive health diagnostics for clinical laboratories and healthcare providers.
Companies that use CyberGene
Customer profileSegments1 record
Ideal customer profiles1 record
CyberGene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CyberGene partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Devyser Diagnostics ABcoreDevyser acquired 100% of CyberGene shares from Level Bio AB for approximately SEK 12.2 million through a directed issue of new shares. The acquisition was completed on April 1, 2026, after receiving regulatory clearance from the Inspectorate of Strategic Products. This acquisition strengthens Devyser's product portfolio in aneuploidy and male infertility testing.
Scale indicators2 records
Recent moves5 records
Expansion highlights3 records
CyberGene competitors and assessment
Company assessmentBroad incumbents
- Bio-Rad Laboratories, Inc. Clinical diagnostics and life science research company with products in molecular testing and quality controls; comparable to CyberGene in providing laboratory-grade diagnostic products for genetic testing laboratories.
- Thermo Fisher Scientific Inc. Major life sciences tools and diagnostics provider offering qPCR and NGS-based assays used in aneuploidy screening and infertility testing; competes broadly in molecular diagnostics workflows relevant to CyberGene.
- QIAGEN N.V. Global molecular diagnostics and sample technologies company offering genetic testing kits and assays across reproductive health and hereditary disease; overlaps with CyberGene's molecular IVD product category.
- Hologic, Inc. Diversified diagnostics and women's health company with a strong portfolio in cytogenetic and prenatal screening assays; directly competes with CyberGene in the aneuploidy/PGT testing category through its diagnostic solutions business.
- Revvity (formerly PerkinElmer Life Sciences): Provides reproductive health and genetic testing products, including aneuploidy screening reagents, serving clinical and reference laboratories; comparable to CyberGene in molecular diagnostics for reproductive genetics.
- CooperSurgical: Global provider of medical devices and genetic testing services focused on women's health, fertility, and reproductive diagnostics; overlaps with CyberGene's aneuploidy and infertility testing offerings within a much broader portfolio.
- Illumina, Inc. Dominant NGS platform provider whose technology underpins many aneuploidy and reproductive-genetics tests globally; an enabling incumbent whose sequencing technology competes with or enables products like CyberGene's.
Direct peers
- Vitrolife AB: Swedish-listed company providing products and services for assisted reproductive technology (ART), including IVF consumables and genetic testing solutions; directly comparable to CyberGene in serving the reproductive-health diagnostics customer base.
- Devyser Diagnostics AB: Swedish molecular diagnostics company specializing in hereditary disease and oncology testing kits; acquired CyberGene in April 2026, directly integrating its aneuploidy and male infertility product lines into Devyser's diagnostic test portfolio.
Emerging players
- Yourgene Health (a Sonic Genetics brand): UK-based molecular diagnostics company specializing in reproductive health and aneuploidy screening (notably NIPT); a more focused emerging competitor directly comparable to CyberGene in the aneuploidy testing niche.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
CyberGene social profiles
Digital presenceCyberGene financial estimates
Financial estimateRevenue estimate
Valuation estimate
CyberGene leadership team
Management profileNumber of profiles
CyberGene funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CyberGene M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CyberGene
What does CyberGene do?
CyberGene is a Swedish molecular diagnostics company that develops and markets diagnostic testing products in two areas: aneuploidy testing (detecting chromosomal abnormalities in prenatal and reproductive health contexts) and male infertility testing. The products are sold to medical diagnostic laboratories and healthcare providers, supporting reproductive-health and genetic-screening workflows.
Is CyberGene a public or private company?
CyberGene is a private company. It is classified as corporate owned and is currently acquired.
When was CyberGene founded?
CyberGene was founded in 1995. It employs 1 to 10 people.
Where is CyberGene based?
CyberGene is headquartered in Solna, Sweden, in the Europe region.
Who are CyberGene's main competitors?
Broad incumbents on record are Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Hologic, Inc., Revvity (formerly PerkinElmer Life Sciences), CooperSurgical and Illumina, Inc.. Direct peers are Vitrolife AB and Devyser Diagnostics AB. Yourgene Health (a Sonic Genetics brand) is listed as an emerging player.
Does CyberGene have an API?
No public API is recorded for CyberGene.
What industry is CyberGene in?
CyberGene's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 325413 and its SIC code is 2835.